Significant CHOZN® Titer Gains: How MilliporeSigma Leveraged Nexxys and Culture’s Cloud Bioreactor Platform
MilliporeSigma partnered with Culture Biosciences to run large, data-rich experiments through Nexxys, our upstream development service that combines Stratyx’s bioreactor technology with Console, our secure, cloud-connected bioprocessing platform. The result: robust, reproducible performance gains, including significant increases in final titer for multiple CHOZN® cell lines producing recombinant therapeutic proteins.
By leveraging Nexxys, MilliporeSigma expanded beyond the limits of in-house capacity while maintaining the control, transparency and data quality. Even better, when they scaled up their PD reactors at Millipore, they achieved titer increases comparable to those observed at Culture Biosciences, demonstrating efficient scale-up performance and confidence in downstream decision-making.
Nexxys effectively acts as an extension of MilliporeSigma’s own upstream development environment, providing scale, speed, and visibility while preserving scientific rigor.
Extend In-House Capacity with Nexxys By:
- Supplementing internal bioreactor capacity with Nexxys’ high-throughput, cloud-connected reactors.
- Running large-scale Design of Experiments (DOE) campaigns without adding internal infrastructure or headcount.
- Maintaining continuous remote access to real-time process data through the Culture Cloud Platform.
- Accelerating program decisions with higher confidence than traditional, lower-throughput industry approaches.
Read the MilliporeSigma White Paper to Learn More.
